Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2008

View Archived Issues

Escitalopram effective in treating multisomatoform disorder

NK-012 evaluated in phase I study in advanced cancer patients

Ki-20227 shows rheumatoid arthritis treatment potential in vivo

Recent patents describe new treatments for cardiovascular disorders

New therapeutic agents for genitourinary disorders reported in recent Roche patent

Florida International University patent discloses novel free radical scavengers

Otsuka and OncoTherapy Science enter license agreement for pancreatic cancer vaccine

Exercise-induced NMDA receptor activity prevents mature motor unit death in SMA

Bone Medical reports positive data from second clinical trial of CaPTHymone for osteoporosis

Epix reaches agreement with FDA for resubmission of Vasovist NDA

Solvay submits complete response to FDA approvable letter for Luvox CR

Eisai temporarily withdraws Japanese application for Pariet to conduct additional study

European Commission approves Novartis' Galvus as oral treatment for type 2 diabetes

Auris Medical completes patient enrollment in phase I/II trial with AM-101

Glenmark to get back global rights to melogliptin from Merck Serono

Pipex to meet with FDA following non acceptance of Coprexa NDA

Asmanex Twisthaler approved for asthma maintenance treatment in children

FDA grants orphan drug designation to VQD-002 in multiple myeloma

EU Commission grants broad approval of Xeloda in metastatic colorectal cancer

FDA approves Endeavor zotarolimus-eluting stent for clogged arteries

BioLineRx reports positive results from phase IIa BL-1020 trial in schizophrenia

Genzyme and Isis granted Hart-Scott-Rodino clearance for collaboration agreeement

First patient dosed in phase II trial of AGI-004 in chemotherapy-induced diarrhea

MedImmune submits BLA for motavizumab in the U.S.

EMEA grants positive opinion for GSK's Hycamtin in relapsed SCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...